A novel serum microRNA panel to discriminate benign from malignant ovarian disease

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 628-636

  Langhe, Ream ^a   Norris, Lucy ^a   Saadeh, Feras Abu ^a   Blackshields, Gordon ^a   Varley, Rachel ^a   Harrison, Ashling ^a   Gleeson, Noreen ^a   Spillane, Cathy ^b   Martin, Cara ^b   O'Donnell, Dearbhaile M ^a   D'Arcy, Tom ^a   O'Leary, John ^a,b   O'Toole, Sharon ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b Tallaght and Coombe Women's and Infant's University Hospital   (Ireland)

Author keywords

MicroRNAs; Panel; Serous ovarian cancer; Serum

Indexed keywords

LET 7I 5P MICRORNA; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 122; MICRORNA 152 5P; MICRORNA 25 3P; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE B; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYSTADENOMA; DOWN REGULATION; FEMALE; HEMOLYSIS; HUMAN; HUMAN TISSUE; OVARY CARCINOMA; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA ISOLATION; WNT SIGNALING PATHWAY; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; CYSTADENOCARCINOMA, SEROUS; FOLLOW UP; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMOLYSIS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84919481010     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.10.010     Document Type: Article

References (61)

1. J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, etal. Cancer incidence and mortality worldwide. 2013.
2. Urban N., Drescher C. Potential and limitations in early diagnosis of ovarian cancer. Adv. Exp. Med. Biol 2008, 622:3-14.
3. Badgwell D., Bast R.C. Early detection of ovarian cancer. Dis. Markers 2007, 23(5-6):397-410.
4. Goff B.A., Mandel L., Muntz H.G., Melancon C.H. Ovarian carcinoma diagnosis. Cancer 2000, 89(10):2068-2075.
5. Skates S.J., Jacobs I.J., Knapp R.C. Tumor markers in screening for ovarian cancer. Methods Mol. Med 2001, 39:61-73.
6. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67(18):8699-8707.
7. Calin G.A., Croce C.M. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006, 66(15):7390-7394.
8. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
9. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294(5543):853-858.
10. Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001, 294(5543):858-862.
11. Miska E.A. How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev 2005, 15(5):563-568.
12. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6(4):259-269.
13. Gregory R.I., Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res 2005, 65(9):3509-3512.
14. Vang S., Wu H.T., Fischer A., Miller D.H., MacLaughlan S., Douglass E., et al. Identification of ovarian cancer metastatic miRNAs. PLoS ONE 2013, 8(3):e58226.
15. Chung Y.W., Bae H.S., Song J.Y., Lee J.K., Lee N.W., Kim T., et al. Detection of MicroRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patient. Int. J. Gynecol. Cancer 2013, 23(4):673-679.
16. Qin W., Ren Q., Liu T., Huang Y., Wang J., et al. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett 2013, 587:1434-1439.
17. He J., Jing Y., Li W., Qian X., Xu Q., Li F.S., et al. Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis. PLoS ONE 2013, 8(2):e56647.
18. Gallagher M.F., Flavin R.J., Elbaruni S.A., McInerney J.K., Smyth P.C., Salley Y.M., et al. Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients. J. Ovarian Res 2009, 2:19.
19. Flavin R., Smyth P., Barrett C., Russell S., Wen H., Wei J., et al. miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int. J. Gynecol. Cancer 2009, 19(4):641-647.
20. Flavin R.J., Smyth P.C., Laios A., O'Toole S.A., Barrett C., Finn S.P., et al. Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Mod. Pathol 2009, 22(2):197-205.
21. Laios A., O'Toole S., Flavin R., Martin C., Kelly L., Ring M., et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol. Cancer 2008, 7:35.
22. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(30):10513-10518.
23. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18(10):997-1006.
24. Chim S.S., Shing T.K., Hung E.C., Leung T.Y., Lau T.K., Chiu R.W., et al. Detection and characterization of placental microRNAs in maternal plasma. Clin. Chem 2008, 54(3):482-490.
25. Gilad S., Meiri E., Yogev Y., Benjamin S., Lebanony D., Yerushalmi N., et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 2008, 3(9):e3148.
26. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol 2008, 141(5):672-675.
27. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol 2008, 110(1):13-21.
28. Hunter M.P., Ismail N., Zhang X., Aguda B.D., Lee E.J., Yu L., et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 2008, 3(11):e3694.
29. Shapira I., Oswald M., Lovecchio J., Khalili H., Menzin A., Whyte J., et al. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br. J. Cancer 2014, 110(4):976-983.
30. Cheng H., Shi S., Cai X., Long J., Xu J., Liu C., et al. microRNA signature for human pancreatic cancer invasion and metastasis. Exp. Ther. Med 2012, 4(2):181-187.
31. Resnick K.E., Alder H., Hagan J.P., Richardson D.L., Croce C.M., Cohn D.E., et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol 2009, 112(1):55-59.
32. Guo F., Tian J., Lin Y., Jin Y., Wang L., Cui M. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma. J. Int. Med. Res 2013, 41(5):1456-1461.
33. Xu Y.Z., Xi Q.H., Ge W.L., Zhang X.Q. Identification of Serum MicroRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac. J. Cancer Prev 2013, 14(2):1057-1060.
34. Hong F., Li Y., Xu Y., Zhu L. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J. Int. Med. Res 2013, 41(1):64-71.
35. Jensen S.G., Lamy P., Rasmussen M.H., Ostenfeld M.S., Dyrskjøt L., Orntoft T.F., et al. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics 2011, 12:435.
36. Andersen C.L., Jensen J.L., Ørntoft T.F. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004, 64(15):5245-5250.
37. Backes C., Leidinger P., Keller A., Hart M., Meyer T., Meese E., et al. Blood born miRNAs signatures that can serve as disease specific biomarkers are not significantly affected by overall fitness and exercise. PLoS ONE 2014, 9(7):e102183.
38. Leidinger P., Backes C., Blatt M., Keller A., Huwer H., Lepper P., et al. The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases. Mol. Cancer 2014, 13:202.
39. Pradervand S., Weber J., Thomas J., Bueno M., Wirapati P., Lefort K., et al. Impact of normalization on miRNA microarray expression profiling. RNA 2009, 15(3):493-501.
40. Ohlsson Teague E.M., Van der Hoek K.H., Van der Hoek M.B., Perry N., Wagaarachchi P., Robertson S.A., et al. MicroRNA-regulated pathways associated with endometriosis. Mol. Endocrinol 2009, 23(2):265-275.
41. Chakrabarty A., Tranguch S., Daikoku T., Jensen K., Furneaux H., Dey S.K. MicroRNA regulation of cyclooxygenase-2 during embryo implantation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(38):15144-15149.
42. Kodahl A.R., Zeuthen P., Binder H., Knoop A.S., Ditzel H.J. Alterations in circulating miRNA levels following early-stage estrogen receptor-positive breast cancer resection in post-menopausal women. PLoS ONE 2014, 9(7):e101950.
43. Sorensen S.S., Nygaard A.B., Nielsen M.Y., Jensen K., Christensen T. miRNA expression profiles in cerebrospinal fluid and blood of patients with acute ischemic stroke. Transl. Stroke Res 2014, Aug 17. [Epub ahead of print].
44. Blondal T., Jensby Nielsen S., Baker A., Andreasen D., Mouritzen P., Wrang Teilum M., et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 2013, 59(1):S1-S6.
45. Pritchard C.C., Kroh E., Wood B., Arroyo J.D., Dougherty K.J., Miyaji M.M., et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev. Res 2012, 5(3):492-497.
46. Kirschner M.B., Kao S.C., Edelman J.J., Armstrong N.J., Vallely M.P., van Zandwijk N., et al. Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE 2011, 6(9):e24145.
47. Yang N., Kaur S., Volinia S., Greshock J., Lassus H., Hasegawa K., et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008, 68(24):10307-10314.
48. D'Adhemar C.J., Gallagher S.C., Bates M.F., Costello M., Barry K., O'Crowley J., et al. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. PLoS ONE 2014, 9:e100816.
49. Liu K., Qian T., Tang L., Wang J., Yang H., Ren J. Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J. Surg. Oncol 2012, 10:225.
50. Wang B., Wang H., Yang Z. MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. PLoS ONE 2012, 7(10):e47053.
51. Zhou X., Zhao F., Wang Z.N., Song Y.X., Chang H., Chiang Y., et al. Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol. Rep 2012, 27(2):447-454.
52. Xiang Y., Ma N., Wang D., Zhang Y., Zhou J., Wu G., et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 2013, 33:378-386.
53. Zhu C., Li J., Ding Q., Cheng G., Zhou H., Tao L., et al. miR-152 controls migration and invasive potential by targeting TGFalpha in prostate cancer cell lines. Prostate 2013, 73(10):1082-1089.
54. Zhang H., Zuo Z., Lu X., Wang L., Wang H., Zhu Z. MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol. Rep 2012, 27(2):594-598.
55. Gatcliffe T.A., Monk B.J., Planutis K., Holcombe R.F. Wnt signaling in ovarian tumorigenesis. Int. J. Gynecol. Cancer 2008, 18(5):954-962.
56. Trinh X.B., van Dam P.A., Dirix L.Y., Vermeulen P.B., Tjalma W.A. The rationale for mTOR inhibition in epithelial ovarian cancer. Expert Opin. Investig. Drugs 2009, 18(12):1885-1891.
57. Smolle E., Taucher V., Pichler M., Petru E., Lax S., Haybaeck J. Targeting signaling pathways in epithelial ovarian cancer. Int. J. Mol. Sci 2013, 14(5):9536-9555.
58. Masoumi Moghaddam S., Amini A., Morris D.L., Pourgholami M.H. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 2012, 31(1-2):143-162.
59. Kelly M.G., Alvero A.B., Chen R., Silasi D.A., Abrahams V.M., Chan S., et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006, 66(7):3859-3868.
60. Chen R., Alvero A.B., Silasi D.A., Steffensen K.D., Mor G. Cancers take their Toll - the function and regulation of Toll-like receptors in cancer cells. Oncogene 2008, 27(2):225-233.
61. Zhu Y., Huang J.M., Zhang G.N., Zha X., Deng B.F. Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells. J. Transl. Med 2012, 10:77.